Asa Waldstein, Principal, Supplement Advisory Group:

"Looking at the past can help predict future regulatory enforcement. There has been no FDA enforcement of claims made on TikTok, and FTC’s enforcement has been limited to a few cases in which notable influencers did not disclose material connections. I expect this minimal enforcement to ramp up over the next year. Also, I predict more FDA biomarker enforcement, which up until this point has only involved heart disease-related statements like “reduces LDL.” This big question is “Will FDA also target GLP-1 statements?” I suspect we will see this appear in some supplement warning letters, but only when higher-risk statements like “prevents obesity” and cringeworthy “nature’s Ozempic” phrases are present."

Read the full article here.